Regeneron Pharmaceuticals, Inc. (REGN)

業務介紹

再生元製藥公司(Regeneron Pharmaceuticals, Inc.)在全球範圍內發現、發明、開發、製造和商業化用於治療各種疾病的藥物。該公司的產品包括:

- EYLEA注射液,用於治療濕性老年性黃斑變性、糖尿病性黃斑水腫、近視性脈絡膜新生血管以及糖尿病視網膜病變,以及視網膜靜脈阻塞後黃斑水腫(包括中央視網膜靜脈阻塞後黃斑水腫和支配性視網膜靜脈阻塞後黃斑水腫)。

- Dupixent注射液,用於治療成人和兒童的特應性皮炎和哮喘。

- Libtayo注射液,用於治療轉移性或局部晚期皮膚鱗狀細胞癌。

- Praluent注射液,用於治療成人異常高膽固醇血症或臨床動脈粥樣硬化性心血管疾病。

- REGEN-COV,用於治療COVID-19。

- Kevzara溶液,用於治療成人類風濕性關節炎。

此外,該公司還提供Inmazeb注射液(用於治療由扎伊爾埃博拉病毒引起的感染)、ARCALYST注射液(用於治療包括家族性寒冷自主性綜合徵和米克爾-威爾斯綜合徵在內的低溫性周期性綜合徵)和ZALTRAP注射液(用於靜脈輸注治療轉移性結直腸癌)。該公司還在開發用於治療眼部、過敏和炎症、心血管和代謝、感染性和罕見疾病以及癌症、疼痛和血液疾病的產品候選藥物。該公司與多家製藥公司有合作和許可協議,並與美國衛生和公共服務部、Zai Lab Limited、Intellia Therapeutics, Inc.、生物醫學高級研究開發局和AstraZeneca PLC有協議。該公司成立於1988年,總部位於紐約州塔利敦。



Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

公司網址

https://www.regeneron.com